Product News
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI